UCL Institute of Neurology
Research and teaching excellence
The Institute of Neurology has a world class reputation for neuroscience. The mission is to translate neuroscience discovery research into treatments for patients with neurological diseases. A number of important research centres are based at the Institute, including the MRC Prion Unit, MRC Centre for Neuromuscular Diseases and the Wellcome Centre for Human Neuroimaging
Professor Michael Hanna is the Director of the Institute, which is a specialist postgraduate institute of University College London, the top-ranked university in the UK for research in Psychology, Psychiatry and Neuroscience.
The Institute is closely associated in its work with the National Hospital for Neurology & Neurosurgery. In combination they form a national and international centre at Queen Square for teaching, training and research in neurology and allied clinical and basic neurosciences.
What We Do
Please see our Infographic highlighting key data on the Institute.
We are delighted to announce that Dr Vafa Alakbarzade has been awarded European Stoke Organisation Young Investigator Award 2017 for her project undertaken at UCL Institute of Neurology/National Hospital for Neurology and Neurosurgery (UCLH), under the supervision of Dr Arvind
Chandratheva and Dr Rob Simister, Consultant Neurologist
& Clinical Lead, UCLH HASU. Dr Simister is also a Faculty member of the MSc Stroke Medicine, UCL Institute of Neurology.
Published: May 22, 2017 10:00:19 AM
Dr Ed Wild of the UCL Huntington’s Disease Centre (UCL
Institute of Neurology) has been invited by Pope Francis to attend the
Vatican on Thursday 18th May as part of HDdennomore, an event
highlighting the plight of Huntington’s disease (HD) sufferers around
the world. Dr Wild received the invitation in recognition of his
research, clinical care and public engagement into HD; as one of a few
specially selected guests, he will also get the chance to meet the Pope
Published: May 18, 2017 9:57:01 AM
UCL Institute of Neurology researcher is leading a phase 3 trial involving more than 1,000
people with multiple sclerosis (MS) to investigate whether simvastatin
could become a treatment for the condition
Published: May 9, 2017 11:05:22 AM